Tigermed and Accerise Announce Joint Venture
November 27, 2019
Hangzhou Tigermed Consulting Co., Ltd. (hereinafter referred to as “Tigermed”) and Accerise Inc. (hereinafter referred to as “Accerise”) jointly announced to establish a joint venture on January 6th, 2020 to provide international multicenter clinical trial services in Japan, and offer supportive services for the global development of domestic pharmaceutical and medical equipment enterprises.
The name of the joint venture company is Tigerise Inc., (hereinafter referred to as Tigerise), Chief Executive Officer is Hiroshi Tsujimoto (Executive Director of Accerise), with registered capital of 20 million yen (Investment ratio: Tigermed accounts for 50%, Accerise accounts for 50%), company address is the same as the Accerise address (two addresses in Chiyoda-ku, Tokyo1 and Kita-ku, Osaka2).
“For this cooperation, the decisions and actions taken by both parties are very conclusive and quick. I believe this high efficiency will also become a major feature of Tigerise.” said Toshiaki Shishido, CEO of Accerise, “As a late arriver in the Japanese CRO field, Accerise will establish a new clinical development business system through the establishment of Tigerise, a joint venture with Tigermed.”
“Participating in Japanese market is an important step of Tigermed’s international strategic layout.” said Ye Xiaoping, Chairman of Tigermed, “Accerise has a wealth of professional talents. Through this joint venture we can meet customer’s requirements more rapidly and comprehensively, which will also contribute to accelerating global development of innovative drugs. “
- Accerise Tokyo Address：4F，1-11 Kanda-Ogawamachi，Chiyoda-Ku Tokyo，101-0052 Japan
- Accerise Osaka Address: 9F，1-5-17 Dojima，Kita-Ku Osaka，530-0003 Japan）
Accerise is developing human resources business and drug development business (CRO) that mainly focus on CRA dispatching, MR dispatching (CSO), professional recruitment of employees. Our excellent and talented people in various fields will enhance customer value by addressing the business and became a member of the client, also, it provides a place for growth of individual employees can be accelerated.
Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality. Headquartered in Hangzhou, Tigermed operates 32 subsidiaries, 95 offices across China and 12 overseas offices in Hong Kong China, Taiwan China, USA, Switzerland, Korea, Australia, Japan, Malaysia, Singapore , India and Romania with over 4100 full time staffs. Tigermed has serviced more than 600 local and global clients in the conduct of over 1060 clinical trials. Tigermed is recognized as “The Innovative CRO” in China，owning to our involvement of over 150 innovative drugs.